Accessibility navigation

Biologically active compound conjugated to a stapled or stitched peptide

Sutura Therapeutics LTD (2017) Biologically active compound conjugated to a stapled or stitched peptide. WO2017109494.

Text (Patent publication document) - Published Version
· Please see our End User Agreement before downloading.


It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Official URL:


[0001] The present invention relates to improvements in drug delivery. [0002] More particularly it relates to the use of Cell Penetrating Agents (CPA’s), and more particularly still to the use of Cell Penetrating Peptides (CPP’s) which have been stabilized 5 by, for example: i) stapling two amino acids to form Stapled CPP’s (StaP’s) or ii) stitching three or more amino acids to form stitched CPP’s (StiP’s). [0003] These stabilized CPP’s are conjugated to a drug or Biologically Active Compound (BAC) directly or via a Bi-Functional Linker (BFL) so that the BAC can be carried though a cell membrane by the CPP. The resulting molecules are referred to as Drug Carrying Cell 10 Penetrating Molecules (DCCPM’s). [0004] The preferred BAC’s delivered in this manner are oligonucleotides (ON’s), more preferably still electrically low charge carrying oligonucleotides (charge -3 to +3 at pH 7.5) and most preferably electrically neutral oligonucleotides (charge -1 to +1 at pH 7.5), such as, but not limited to, polynucleic acids (PNAs), phosphorodiamidate morpholino oligonucleotides (PMO’s) 15 or modified derivatives thereof. [0005] The preferred BFL may be PEGylated, comprising poly ethylene glycol (PEG) groups including modifications such as an amine group, or incorporate a spacer, such as -Ala. These modifications can improve solubilisation or provide appropriate spacing between functional moieties. 20 [0006] The invention also relates to a method of facilitating the uptake of a BAC into a cell, the use of a DCCPM in the treatment of a disease requiring alteration of an endogenous or exogenous gene, a method of improving the bioavailability of a drug or BAC, a method of introducing a drug or BAC to a site which is refractory to the drug or BAC in its native state, a method of treating a subject comprising administering the DCCPM’s of the invention and to a 25 pharmaceutical composition comprising the DCCPM and one or more pharmaceutically acceptable excipients. [0007] Still further aspects will be apparent from the detailed description.

Item Type:Patent
Divisions:Life Sciences > School of Biological Sciences > Biomedical Sciences
ID Code:77218


Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation